No Cover Image

Journal article 87 views 48 downloads

Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease

RAJVANSHI SUTARIA, Zi Hong Mok Orcid Logo

Pharmaceutical Science Advances, Volume: 1, Issue: 2, Start page: 100014

Swansea University Authors: RAJVANSHI SUTARIA, Zi Hong Mok Orcid Logo

  • 65723.pdf

    PDF | Version of Record

    This is an open access article under the CC BY-NC-ND license.

    Download (1.91MB)

Check full text

DOI (Published version): 10.1016/j.pscia.2023.100014

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remain...

Full description

Published in: Pharmaceutical Science Advances
ISSN: 2773-2169
Published: Elsevier BV 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa65723
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2024-03-01T14:54:30Z
last_indexed 2024-03-01T14:54:30Z
id cronfa65723
recordtype SURis
fullrecord <?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>65723</id><entry>2024-03-01</entry><title>Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease</title><swanseaauthors><author><sid>818a65dfaa99c231cb67f61d753df7b4</sid><firstname>RAJVANSHI</firstname><surname>SUTARIA</surname><name>RAJVANSHI SUTARIA</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>4a0b8a58c748d6a2c87a54f263f4d397</sid><ORCID>0000-0002-1231-5048</ORCID><firstname>Zi Hong</firstname><surname>Mok</surname><name>Zi Hong Mok</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-03-01</date><abstract>Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remained a difficulty. Current mesalazine formulations, including tablets, suppositories, and enemas, are typically associated with adverse systemic effects. The use of nanocarriers however has opened the possibility of improved local targeting and pharmacokinetics of loaded mesalazine, based on the new physicochemical properties of the drug vehicle. The innovative nanoencapsulation of mesalazine has demonstrated success in targeting inflammatory regions and treating mild to moderate IBD. The use of nanocarriers, such as lipid-based, polymeric, and inorganic nanocarriers, has demonstrated improved overall solubility, absorption, and bioavailability of mesalazine while minimising the side effects associated with their absorption. This review aims to offer an insight into what is currently known about IBD, and the nanotechnological approaches for the improvement of mesalazine therapy for IBD.</abstract><type>Journal Article</type><journal>Pharmaceutical Science Advances</journal><volume>1</volume><journalNumber>2</journalNumber><paginationStart>100014</paginationStart><paginationEnd/><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2773-2169</issnPrint><issnElectronic/><keywords>Inflammatory bowel disease; Ulcerative colitis; Crohn&amp;apos;s disease; Mesalazine; Nanocarriers</keywords><publishedDay>1</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-12-01</publishedDate><doi>10.1016/j.pscia.2023.100014</doi><url/><notes/><college>COLLEGE NANME</college><CollegeCode>COLLEGE CODE</CollegeCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>Shandong University</funders><projectreference/><lastEdited>2024-04-25T22:15:28.9618635</lastEdited><Created>2024-03-01T14:50:03.4001951</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Pharmacy</level></path><authors><author><firstname>RAJVANSHI</firstname><surname>SUTARIA</surname><order>1</order></author><author><firstname>Zi Hong</firstname><surname>Mok</surname><orcid>0000-0002-1231-5048</orcid><order>2</order></author></authors><documents><document><filename>65723__29626__cb5b92282fbc4be0acd732382665e8d5.pdf</filename><originalFilename>65723.pdf</originalFilename><uploaded>2024-03-05T09:12:56.0500459</uploaded><type>Output</type><contentLength>1999186</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This is an open access article under the CC BY-NC-ND license.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc- nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling v2 65723 2024-03-01 Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease 818a65dfaa99c231cb67f61d753df7b4 RAJVANSHI SUTARIA RAJVANSHI SUTARIA true false 4a0b8a58c748d6a2c87a54f263f4d397 0000-0002-1231-5048 Zi Hong Mok Zi Hong Mok true false 2024-03-01 Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remained a difficulty. Current mesalazine formulations, including tablets, suppositories, and enemas, are typically associated with adverse systemic effects. The use of nanocarriers however has opened the possibility of improved local targeting and pharmacokinetics of loaded mesalazine, based on the new physicochemical properties of the drug vehicle. The innovative nanoencapsulation of mesalazine has demonstrated success in targeting inflammatory regions and treating mild to moderate IBD. The use of nanocarriers, such as lipid-based, polymeric, and inorganic nanocarriers, has demonstrated improved overall solubility, absorption, and bioavailability of mesalazine while minimising the side effects associated with their absorption. This review aims to offer an insight into what is currently known about IBD, and the nanotechnological approaches for the improvement of mesalazine therapy for IBD. Journal Article Pharmaceutical Science Advances 1 2 100014 Elsevier BV 2773-2169 Inflammatory bowel disease; Ulcerative colitis; Crohn&apos;s disease; Mesalazine; Nanocarriers 1 12 2023 2023-12-01 10.1016/j.pscia.2023.100014 COLLEGE NANME COLLEGE CODE Swansea University Another institution paid the OA fee Shandong University 2024-04-25T22:15:28.9618635 2024-03-01T14:50:03.4001951 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Pharmacy RAJVANSHI SUTARIA 1 Zi Hong Mok 0000-0002-1231-5048 2 65723__29626__cb5b92282fbc4be0acd732382665e8d5.pdf 65723.pdf 2024-03-05T09:12:56.0500459 Output 1999186 application/pdf Version of Record true This is an open access article under the CC BY-NC-ND license. true eng http://creativecommons.org/licenses/by-nc- nd/4.0/
title Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
spellingShingle Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
RAJVANSHI SUTARIA
Zi Hong Mok
title_short Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
title_full Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
title_fullStr Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
title_full_unstemmed Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
title_sort Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease
author_id_str_mv 818a65dfaa99c231cb67f61d753df7b4
4a0b8a58c748d6a2c87a54f263f4d397
author_id_fullname_str_mv 818a65dfaa99c231cb67f61d753df7b4_***_RAJVANSHI SUTARIA
4a0b8a58c748d6a2c87a54f263f4d397_***_Zi Hong Mok
author RAJVANSHI SUTARIA
Zi Hong Mok
author2 RAJVANSHI SUTARIA
Zi Hong Mok
format Journal article
container_title Pharmaceutical Science Advances
container_volume 1
container_issue 2
container_start_page 100014
publishDate 2023
institution Swansea University
issn 2773-2169
doi_str_mv 10.1016/j.pscia.2023.100014
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Pharmacy{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Pharmacy
document_store_str 1
active_str 0
description Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remained a difficulty. Current mesalazine formulations, including tablets, suppositories, and enemas, are typically associated with adverse systemic effects. The use of nanocarriers however has opened the possibility of improved local targeting and pharmacokinetics of loaded mesalazine, based on the new physicochemical properties of the drug vehicle. The innovative nanoencapsulation of mesalazine has demonstrated success in targeting inflammatory regions and treating mild to moderate IBD. The use of nanocarriers, such as lipid-based, polymeric, and inorganic nanocarriers, has demonstrated improved overall solubility, absorption, and bioavailability of mesalazine while minimising the side effects associated with their absorption. This review aims to offer an insight into what is currently known about IBD, and the nanotechnological approaches for the improvement of mesalazine therapy for IBD.
published_date 2023-12-01T22:15:29Z
_version_ 1797342866341625856
score 11.013148

Similar Items